Collaboration and License Agreement (Details) - ModernaTX, Inc $ / shares in Units, $ in Millions	1 Months Ended
	Mar. 31, 2023 USD ($) product item $ / shares shares	Dec. 31, 2024 USD ($)	Apr. 30, 2023 USD ($)
Share Purchase Agreement | Beneficial Owner
Collaboration and License Agreement
Issuance of common stock, shares | shares	5,859,375
Collaboration and License Agreement
Collaboration and License Agreement
Upfront payments	$ 40.0		$ 40.0
Prepaid research services funding	$ 7.5		$ 7.5
Milestone payments receivable		$ 1,800.0
Number of performance obligations | item	1
Premium paid on common stock	$ 13.3
Variable consideration	$ 0.0
Collaboration and License Agreement | Minimum
Collaboration and License Agreement
Number of products to be commercialized | product	1
Royalty payment term	10 years
Collaboration and License Agreement | Share Purchase Agreement | Beneficial Owner
Collaboration and License Agreement
Issuance of common stock, shares | shares	5,859,375
Shares issue price (in dollars per share) | $ / shares	$ 6.14
Proceeds from issuance/sale of common stock	$ 36.0
Percent of shares to be issued	3.06%
Equity financing	$ 25.0